Lexaria Bioscience (LEXX) Income Statement
Lexaria Bioscience Income Statement
Last quarter (Q3 2026), Lexaria Bioscience's total revenue was $0.00, a decrease of 100.00% from the same quarter last year. In Q3, Lexaria Bioscience's net income was $-1.99M. See Lexaria Bioscience’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Aug 25 | Aug 24 | Aug 23 | Aug 22 | Aug 21 |
|---|---|---|---|---|---|
| $ 705.92K | $ 464.28K | $ 226.21K | $ 255.40K | $ 722.74K | |
| $ 703.20K | $ 459.46K | $ 194.71K | $ 183.56K | $ 547.39K | |
| $ 12.58M | $ 6.21M | $ 6.73M | $ 6.80M | $ 6.23M | |
| Depreciation and Amortization | $ 87.83K | $ 76.15K | $ 145.40K | $ 102.72K | $ 147.60K |
| $ -11.82M | $ -5.73M | $ -6.57M | $ -7.28M | $ -4.02M | |
| $ -11.88M | $ -5.75M | $ -6.53M | $ -6.62M | $ -5.69M | |
| $ -30.70K | $ -55.52K | $ -178.50K | $ -764.61K | $ 1.52M | |
| $ -11.91M | $ -5.81M | $ -6.71M | $ -7.38M | $ -4.16M | |
| $ -11.90M | $ -5.80M | $ -6.66M | $ -7.27M | $ -4.03M | |
| Per Share Metrics | |||||
| Basic EPS | $ -9.90 | $ -7.05 | $ -15.15 | $ -18.60 | $ -13.80 |
| Diluted EPS | $ -9.90 | $ -7.05 | $ -15.15 | $ -18.60 | $ -13.80 |
| Weighted Average Shares Outstanding | 1.20M | 825.60K | 440.94K | 392.35K | 292.76K |
| Weighted Average Shares Outstanding (Diluted) | 1.20M | 825.60K | 440.94K | 392.35K | 292.76K |
Currency in USD
